Clinuvel Pharmaceuticals Ltd Ordinary Shares (Australia) · CLVLF

Exhibit 99.1

6-K · 2026-10-07 · 0001493152-26-046056

Exhibit 99.2

6-K · 2026-10-07 · 0001493152-26-046056

Exhibit 99.1

6-K · 2026-10-02 · 0001493152-26-045459

Exhibit 99.1 SCENESSE® response in vitiligo: new cases from the CUV105 trial presented to EADV Melbourne / Singapore - 1 October 2026 - CLINUVEL PHARMACEUTICALS LTD (ASX: CUV | Nasdaq: CUVL) today announced that new patient cases demonstrating the clinical response to SCENESSE® (afamelanotide) with adjunct narrowband ultraviolet B (NB-UVB) phototherapy in vitiligo patients are being presented to the European Academy of Dermatology and Venerology (EADV) conference in Vienna. Treatment effect i…

6-K · 2026-10-01 · 0001493152-26-045210

Exhibit 99.1 CLINUVEL develops proprietary ZEROKIN™ device Single-use administration device for controlled-release formulations Executive Summary ZEROKIN™ novel single-use administration device for controlled-release formulations IP application submitted commercial manufacturer to be appointed dossier for Class II to be submitted as FDA 510(k) Figure 1. Illustration of single-use administration device ZEROKIN™ Melbourne / Singapore - 08 September 2026 - CLINUVEL PHARMACEUTICALS L…

6-K · 2026-09-09 · 0001493152-26-041832

Exhibit 99.1

6-K · 2026-08-27 · 0001493152-26-040352